SaferSkin™ Launched at SOT

SaferSkin™
- integrated skin sensitisation assessment

An estimated 15-20% of the general population suffers from allergic contact dermatitis, or skin sensitisation. In fact, skin sensitisation is considered the most prevalent form of immunotoxicity found in humans, responsible for over seven million outpatient visits annually.*

SaferSkin™ is an easy-to-use software application which helps you determine, with confidence, the skin sensitisation potency of a substance according to accepted OECD guidelines. Applying three different and well-accepted scientific approaches, SaferSkin™ assesses input data, assigns a sensitisation category and calculates the level of confidence in the prediction. In one step, SaferSkin™ can help you make the best decisions in line with regulatory guidelines and best industry practices. SaferSkin™ supports the principles of the 3Rs of animal testing (Reduction, Refinement, Replacement) for more humane research.

Openness and transparency is in our company’s DNA so the SaferSkin™ Basic version is free and available to the global community. SaferSkin™ Professional offers additional and more advanced features at an affordable rate. The Enterprise version offers you the opportunity to define features for SaferSkin™ that are customised to your specific needs.

SaferSkin™ is the first of a range of chemical safety applications we have in the pipeline.

 

Get in touch for a free trial, or visit https://saferworldbydesign.com/saferskin/

 


* Kimber I, Basketter DA, Gerberick GF, Dearman RJ (2002). "Allergic contact dermatitis". Int. Immunopharmacol. 2 (2–3): 201–11. doi:10.1016/S1567-5769(01)00173-4. PMID 11811925

About Edelweiss Connect

Edelweiss Connect manages collaborative projects to achieve goals in scientific research, infrastructure development or service provision. Effective collaboration requires many elements including coordination, culture, communications, common understanding, decision-making and interoperability.

Tags

Latest Tweets

Edelweiss Connect (3 days ago)
RT @openrisknet: Read about our latest achievements on the federation of computing and data resources between the @OpenRiskNet #einfrastruc…
Edelweiss Connect (2 weeks ago)
RT @EU_ToxRisk: Next week, @EU_ToxRisk workshop open to experts with interest and background into #regulatory science. Focus: regulatory as…
Edelweiss Connect (2 weeks ago)
Our May 2019 newsletter highlights the upcoming @openrisknet webinars, the May 21-22 free training on New Approach… https://t.co/eYqFaD51iA
Edelweiss Connect (3 weeks ago)
Rich metadata for richer results - learn how AI approaches are increasing the need for rich metadata:… https://t.co/Aj68GoQYTI
Edelweiss Connect (4 weeks ago)
RT @barryhardy: Automated & Integrated Workflow for Adverse Outcome Pathway Identification, Hypothesis Generation & Risk Assessment, Webina…

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland
  • Phone: +41 61 633 29 78
  • Email: info@edelweissconnect.com

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA
  • Phone: +1 252 654 9003
  • Email: info@edelweissconnect.com